Elanco (ELAN) CEO Jeffrey Simmons reports new deferred stock units

Rhea-AI Filing Summary

Elanco Animal Health Inc. insider Jeffrey N. Simmons, the company’s President, CEO and Director, reported an acquisition of derivative securities in the form of deferred stock units on 12/26/2025. The filing shows he acquired 122.5327 deferred stock units tied to Elanco common stock at a derivative price of $22.6 per unit. Following this transaction, he beneficially owns 18,727.5311 deferred stock units directly.

Each deferred stock unit represents the right to receive one share of Elanco common stock or the cash equivalent. These units are scheduled to settle in cash or shares of Elanco common stock after termination of employment or during a specified future year under the company’s Executive Deferral and Stock Match Plan.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Simmons Jeffrey N

(Last) (First) (Middle)

C/O ELANCO ANIMAL HEALTH INCORPORATED

450 ELANCO CIRCLE

(Street)

INDIANAPOLIS IN 46221

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Elanco Animal Health Inc [ ELAN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	PRESIDENT, CEO AND DIRECTOR

3. Date of Earliest Transaction (Month/Day/Year)
12/26/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Deferred Stock Units	(1)	12/26/2025		A		122.5327		(2)	(2)	Common Stock	122.5327	$22.6	18,727.5311	D

Explanation of Responses:

1. Each deferred stock unit represents the right to receive one share of Company common stock or the cash equivalent.

2. Deferred stock units settle in cash or shares of Company common stock following termination of employment or during a specified future year in accordance with Executive Deferral and Stock Match Plan.

	/s/ Amy C. Seidel, as Attorney-in-Fact for Jeffrey N. Simmons	12/30/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did ELAN’s CEO report on this Form 4?

Jeffrey N. Simmons, President, CEO and Director of Elanco Animal Health Inc. (ELAN), reported acquiring 122.5327 deferred stock units tied to Elanco common stock on 12/26/2025.

How many deferred stock units does ELAN’s CEO hold after this transaction?

After the reported transaction, Jeffrey N. Simmons beneficially owns 18,727.5311 deferred stock units, held directly.

What does each deferred stock unit represent for Elanco (ELAN)?

Each deferred stock unit represents the right to receive either one share of Elanco common stock or the cash equivalent, as described in the filing.

When will the Elanco (ELAN) deferred stock units reported by the CEO settle?

The deferred stock units settle in cash or shares of Elanco common stock following termination of employment or during a specified future year under the company’s Executive Deferral and Stock Match Plan.

Is the reported Elanco (ELAN) transaction a derivative security?

Yes. The filing classifies the instrument as a derivative security in the form of deferred stock units linked to Elanco common stock.

What role does Jeffrey N. Simmons hold at Elanco (ELAN)?

Jeffrey N. Simmons is identified as President, CEO and Director of Elanco Animal Health Inc. in the filing.